Updates in GU [2023] Interview - Mar, MD - MOASC

The interview covered crucial aspects of oncology treatment decisions. It emphasized the need to assess eligibility for cisplatin-based chemotherapy in muscle-invasive bladder cancer patients, discussed the importance of neoadjuvant chemotherapy based on the Vesper, Contact-03 and Talapro Pro results.


Nataliya Mar, MD Clinical Associate Professor in the Division of Hematology/Oncology at the University of California Irvine, provides GU ASCO Updates [2023].

What were the VESPER trial results? 

What were the CONTACT-03 trial results? 

In the case of the 68-year-old man with metastatic prostate cancer, who had initial response but then developed PSA rise, what are the key considerations when selecting treatment options for patients with somatic and germline DDR alterations? How do PARP inhibitors fit into the treatment landscape?

What were the TALAPRO-2 trial results?